$2.33-0.02 (-0.85%)
Grace Therapeutics, Inc.
Grace Therapeutics, Inc. in the Healthcare sector is trading at $2.33 with a market capitalization of $39M. Wall Street consensus targets $5.99 (2 analysts), implying a +157.3% move over the next 12 months. The stock is currently near its 52-week low of $1.79, remaining 27.6% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$3.01M↓ | -$2.45M↑ | -$2.53M↑ | -$3.09M↑ | -$3.18M |
| Net Income | -$1.18M↑ | -$2.31M↓ | -$938,000↑ | -$3.36M↓ | $636,000 |
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an injectable formulation developed to treat aneurysmal ...
Health care stocks were softer late Thursday afternoon, with the NYSE Health Care Index and the Stat
Just because a business does not make any money, does not mean that the stock will go down. For example, Grace...
Insiders were net buyers of Grace Therapeutics, Inc.'s ( NASDAQ:GRCE ) stock during the past year. That is, insiders...
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...